Skip to main content

Michael Levy

Neurologist and director of the NMO Clinic and Research Laboratory at Massachusetts General Hospital; associate professor at Harvard Medical School.

Oct 2, 2026

21:50
Could you take us through the trial design?
21:52
Yeah, so this trial is based on a small series of cases that were treated with the older version of satralizumab called tocilizumab.
22:00
The difference between tocilizumab and satralizumab is dosing frequency.
22:04
Satralizumab is a modified form that stays in circulation longer.
22:08
But tocilizumab has been available for a fair bit of time.
22:11
It's over 15 years old now, and there are biosimilars available.
22:14
And so we have been able to use it off-label.
25:56
For providers who may be a little bit less familiar with satchelizumab, if a patient were to ask, what are the risks associated with this treatment? What counsel would you give them?
48:17
And so I'm going to stop.
48:21
So I was I was thinking about this as you were talking, and I'll just say one snarky thing first around, you know, Republicans holding Democrats to every wild outlandish thing that some activists said online or some slogan that only a very small percentage said.
48:39
I can't wait to hear how when the Democrats come back into the White House in 2029, the Republicans are going to somehow get religion again on the national debt and reducing the $40 trillion in debt that we're in.
48:51
But I think AOC is basically right about the substance.
48:54
And although I hate AOC, you know, that we're talking about this and doing it in software releases for progressive politics of 1.0 and 2.0 and 2.1 and all of that kind of stuff.
49:04
But defund the police was an atrocious slogan for Democrats, even if it was still a small sliver of the Democratic activist base that actually was talking about it.
49:17
Because, you know, when we look at the National Guard, and I was sad that you weren't there to discuss it last week with us, Michael, And Trey and I talked about the National Guard deployment, because if you ask, you know, talk about defund the police and then you ask real people in neighborhoods that are afflicted by crime, like even though they might not want armed police who are responding to every mental health crisis or every homeless situation and rather have different kinds of professionals dealing with that.
54:31
Please
15:42
And so where did the idea come from that Epstein-Barr virus could be linked to multiple sclerosis?
15:48
Well, it, it took a long time to wrap people's heads around this idea because if everyone gets Epstein-Barr virus, then why do only a few people, one in three or 400, get MS? It doesn't really compute.
16:01
And so that's really limited the field for a very long time until a really good study in 2022 demonstrated that without exposure to the Epstein-Barr virus, you cannot get MS.
16:14
And this was a study done in the US military where everyone at age 18 who enrolls in the military gets a blood draw.
16:21
And what they did was they looked at everyone who was initially negative, who'd not yet gotten exposed to the virus, and they pooled all of those samples of people who would eventually get MS and of those who didn't.
16:35
And the ones who got MS invariably got the Epstein-Barr virus infection first and then evidence that there was neurological damage and then clinical onset of MS.
16:48
That was the order of things that had to happen first, second, and third.
20:34
What about trying to prevent people from getting the Epstein-Barr virus in the first place so that they can't then go on to develop MS? Could you see a day when we have a vaccine against it?
0:48
Let's talk about something awesome.
0:50
Okay, let's step way back from the real estate business, and really let's talk, talk about society and our economy and, you know, what's happening in the world that we live in, in the great arc of history, right? The big arcs.
1:04
There's the really big arcs of history, which are hundreds of years, millennials, and you talk about empires falling and declining.
1:09
And maybe let, let's go a little-- zoo-zoom in a little more than that.
1:14
And this is just something that's been on my mind for the past couple of years and affecting the way I think about the world and affecting our, our company and our business.
1:23
When I went to college, which is well in advance of you going to college, it was, I wouldn't say the very beginning, but it really was near the, the, the beginning of let's outsource everything.
1:34
Um, we were taught that, right? Guns and butter, move everything to where it was the lowest cost provider and the competitive advantages that they had.

59 MINS LATER

60:38
Yeah.
6:29
Levy?
6:30
Well, usually people present to an ophthalmologist because they're thinking there's something wrong with their vision.
6:35
And they go in, they get checked out.
6:36
As Dr. Greenberg was saying, most of the time the eye looks fine to the ophthalmologist.
6:41
But since the patient can't see well out of the eye, then the ophthalmologist figures, okay, there must be something wrong with the nerves behind the eye that they can't see.
6:49
So then they send them to the emergency room or to a neuro-ophthalmologist or a neurologist.
6:54
where the first test will be an MRI.

9 MINS LATER

16:07
going to defer to Mike on this one.
4:49
Leidy?
4:51
Yeah, I think a lot of our patients have been on rituximab or a blizna and a blizumab, and they're familiar with the role of B cells.
5:00
And B cells that can produce plasma blasts that make aquaporin-4 antibodies, these immune components are all different.
5:10
involved in the pathology of NMOSD and removing them, removing B cells specifically is helpful.
5:17
That's been, we've been using rituximab since 2005 for NMOSD and anabolizumab since I think 2020.
5:24
And these treatments are remarkably helpful.
5:26
What CAR T offers is an even greater depletion as Dr. Greenberg was saying.
7:19
Levy?
21:54
And are you concerned that people will try to do something like this in the future? Because it appears incredibly dangerous, particularly to do without equipment.
22:02
Yeah, for sure.
22:03
I would first off not advise anyone to go and imitate it themselves.
22:11
But in the social media age and in the age of free solo and death-defying stunts like that, I think that it probably does bring attention, but again, a negative attention, as you kind of say.
22:26
Like most climbers, when they're going out, they're using ropes.
22:29
They're trying to get whatever they are looking to get out of nature or the gym and exercise and this.
22:39
Ultimately, they're getting very high off the ground and it's very dangerous, but it has very little to do with rock climbing.
23:38
But let me ask you, like, climbing a skyscraper, particularly with no equipment, let's say that's what we're talking about, or even with equipment, how is that different from any other kind of structure?
1:00
Michael, could you take us through the results of this trial?
1:04
This was a phase three placebo-controlled blinded study that enrolled 132 participants, randomized one-to-one to either drug or placebo, and followed over a period of about two years.
1:19
And the outcome is that Satchelizumab prevented relapses by about 68% compared to background therapy.
1:28
And can you take us through the context of what this means for patients with MOG antibody disease moving forward?
1:35
This is the first phase three trial that read out in MOG antibody disease, and it'll probably be the first FDA approved drug for MOG
3:48
Now, this agent, the satchelizumab, is an FDA-approved drug for other conditions, but were there any new safety concerns when it was studied in this population?
3:59
Yeah, the drug is satralizumab, which is an interleukin-6 receptor blocker.
4:04
It is approved for aquaporin-4-seropositive neuromyelitis optica spectrum disorder.
4:09
People may recognize the older version of satralizumab, which is called tocilizumab, which is approved for arthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, and vasculitis.
4:22
The newer version, satralizumab, which is approved for NMOSD, is monthly, and it's a subcutaneous injection.
4:30
In the trial for NMOSD, and now we have over five years of safety data, the side effects have been relatively mild.
4:38
We noticed fibrinogen goes down and lipid levels go up a little bit.
7:20
Is there anything else you would like to share with our listeners
3:24
Could you take us through the trial design?
3:27
Yeah.
3:27
So this trial is based on a small series of cases that were treated with the older version of satralizumab called tocilizumab.
3:35
The difference between tocilizumab and satralizumab is dosing frequency.
3:39
Satralizumab is a modified form that stays in circulation longer.
3:43
But tocilizumab has been available for a fair bit of time.
3:46
It's over fifteen years old now, and there are biosimilars available, and so we have been able to use it off-label.
7:31
For providers who may be a little bit less familiar with satralizumab, if a patient were to ask, "What are the risks associated with this treatment?" what counsel would you give them?
Travis KircherCORRESPONDENT
16:04
He also confirms that Hamas gave some of the hostages, for lack of a better term, a grab bag before they were handed over to the Red Cross.
16:14
It's just another demonstration of how sick and twisted they are.
16:18
I mean, they gave them, uh, the, the, the...
16:22
Their version of, uh, souvenirs from Gaza.
16:25
The only thing Or got was a certificate, but I know that from o- other hostages that were released that, uh, some of them got, uh, pictures of, uh, the city of Gaza, a scarf of Hamas, or a headband of Hamas, or something like that.
16:40
[cheering]
Travis KircherCORRESPONDENT
19:45
Michael says it was an emotional moment for both his brother and the team.
19:49
When we got into, to the arena, everyone cried.

We value your privacy

We use cookies to understand how you use our platform and to improve your experience. Click “Accept All” to consent, or “Decline non-essential” to opt out of non-essential cookies. Read our Privacy Policy.